# (19) World Intellectual Property Organization International Bureau



### 

### (43) International Publication Date 12 July 2001 (12.07.2001)

### **PCT**

# (10) International Publication Number WO 01/49669 A1

(51) International Patent Classification7:

C07D 253/07

(21) International Application Number:

PCT/IN00/00001

(22) International Filing Date: 3 January 2000 (03.01.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant (for all designated States except US): RPG LIFE SCIENCES LIMITED [IN/IN]; 21, D Sukhadvala, Mumbai 400 001, Maharashtra (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RADHAKRISH-NAN, Tarur, Venkatasubramanian [IN/IN]; RPG Life Sciences Limited, 25 MIDC Land, Thane-Belapur Road, Navi-Mumbai 400 705, Maharashtra (IN). SASIKUMAR, Thoovara, Mohan [IN/IN]; RPG Life Sciences Limited, 25 MIDC Land, Thane-Belapur Road, Navi-Mumbai 400 705, Maharashtra (IN). SRIVASTAVA, Anita, Ranjan [IN/IN]; RPG Life Sciences Limited, 25 MIDC Land, Thane-Belapur Road, Navi-Mumbai 400 705, Maharashtra (IN).

(74) Agents: DEPENNING, Robert, G. et al.; Depenning & Depenning, Alaknanda, 16 Nepean Sea Road, Mumbai 400 036 (IN).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


#### Published:

With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A PROCESS FOR THE PREPARATION OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE-3,5-DIAMINE, COM-MONLY KNOWN AS LAMOTRIGINE

WO 01/49669 A1



(57) Abstract: A process for the preparation of 6-(2,3dichlorophenyl)-1,2,4-triazine-3-5-diamine (lamotrigine) formula (I). 2,3-Dichloronitrobenzene in C<sub>1</sub>-C<sub>6</sub> aliphatic alkanol is hydrogenated at 55-90 psi gas pressure using metal catalyst at 27-35 °C. 2,3-Dichloroaniline is diazotised and cyano-de-diazonised with metal cyanide at 65-80 °C. 2,3-Dichlorobenzonitrile is hydrolysed and 2,3-dichlorobenzoic acid is chlorinated at 55-130 °C. Cyano-de-halogenation of 2,3-dichlorobenzoyl chloride is carried out with a metal cyanide and alkali metal iodide by refluxing in an aprotic solvent under an inert atmosphere. 2,3-Dichlorobenzoyl cyanide is condensed with aminoguanidine bicarbonate in an organic solvent in acidic conditions using catalyst at 90-125 °C followed by in situ cyclisation of the Schiff's base by refluxing in an aliphatic alkanol with base. Crude lamotrigine is purified.

## TITLE OF INVENTION

A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine.

### **Technical Field**

This invention relates to a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I:

10

5

15

Formula I

commonly known as Lamotrigine.

Lamotrigine, an anti-epileptic drug, elicits its action by suppressing seizures by inhibiting the release of excitatory neurotransmitters. Lamotrigine presently offers a worthwhile alternative for treating patients suffering from nitractable partial seizures coupled with or without secondary generalised seizures and therefore shows good potential for broader applications in other areas of epilepsy management.

10

15

20

25

### **Background Art**

One method of preparation of lamotrigine of the formula I involves reaction of 6-(2,3-dichlorophenyl)-5-chloro-3-thiomethyl-1,2,4-triazine of the formula II:

### Formula II

with ethanolic ammonia in a sealed tube at 180°C/250 psi pressure (PCT Publication No WO 96/20935). This process is time consuming (~ 72 hours) and also produces lamotrigine in low yields because of which it is not commercially viable.

Another route for the synthesis of lamotrigine of the formula I involves photochemical reaction of the compound of the formula III:

$$CI \qquad CI \qquad CI \qquad NH_2$$

$$C = N - N = C \qquad NH_2$$

$$NH_2$$

#### Formula III

where R = CN or  $CONH_2$  using ultraviolet or visible radiation in the presence of a base in an alkanol solvent and also heating when R = CN (PCT Publication No WO 96/20934). The preparation of the compound

of the formula III involves expensive and hazardous reagents. Further, undesired by-products like the de-aminated hydroxy derivative of triazine formed during the photochemical reaction demand elaborate separation and purification techniques, thereby making this route lengthy and tedious, besides producing low yields of lamotrigine (< 10 %). Therefore this process is not suitable for industrial scale manufacture of lamotrigine.

Yet another method for the synthesis of lamotrigine of the formula I involves cyclisation of the Schiff's base of the formula IV:

$$\begin{array}{c|c} C & C & C \\ \hline \end{array}$$

Formula IV

by refluxing in C<sub>1</sub>-C<sub>4</sub> aliphatic alkanol in the presence or absence of a strong base such as KOH (EP Patent No 21121 and US Patents Nos 4602017 and 4847249).

The Schiff's base of the formula IV may be prepared by a sequence of steps comprising:

### (1) reaction of 2,3-dichloroiodobenzene of the formula V:

Formula V

25

15

10

15

20

25

4

with magnesium, followed by reaction of the resulting Grignard moeity with solid carbondioxide;

(2) reaction of the resulting 2,3-dichlorobenzoic acid of the formula VI:

Formula VI

with thionyl chloride in an inert atmosphere such as moisture free nitrogen gas;

(3) reaction of the resulting 2,3-dichlorobenzoyl chloride of the formula VII:

Formula VII

with a metal cyanide and alkali metal iodide such as Cu(one)CN and KI in the presence of an organic solvent such as xylene in an inert atmosphere such as nitrogen; and

(4) reaction of the resulting 2,3-dichlorobenzoylcyanide of the formula VIII:

WO 01/49669 PCT/IN00/00001

5

### Formula VIII

with aminoguanidine bicarbonate in an organic solvent such as DMSO in aqueous acidic medium using 8N HNO<sub>3</sub>. The purification of crude lamotrigine of the formula I thus obtained by cyclisation of the Schiff's base of the formula IV is carried out by recrystallisation from isopropanol (EP Patents Nos 59987 and 21121 and US Patents Nos 4602017 and 3637688).

The formation of 2,3-dichlorobenzoic acid of the formula VI for the preparation of the Schiff's base of the formula IV by the above route demands a dry environment thereby making the process laborious. These reactions leading to the Schiff's base of the formula IV also employ expensive and hazardous reagents like DMSO in large quantities and xylene. The conversion of 2,3-dichlorobenzoyl chloride to 2,3-dichlorobenzoyl cyanide takes 96 hours thereby making the entire process for the synthesis of the Schiff's base from 2,3-dichlorobenzoyl chloride time consuming (~7.5 - 10 days). This route also produces low yields of lamotrigine (~ 1.0 %). Therefore this process for the preparation of lamotrigine is not feasible for industrial scale manufacture.

25

5

10

15

WO 01/49669 PCT/IN00/00001

6

The Schiffs base of the formula IV may also be prepared by the reaction of 2,3-dichlorobenzoyl cyanide of the formula VIII with aminoguanidine bicarbonate in the presence of acetonitrile and dilute aqueous sulfuric acid (US Patent No 4847249). This route for the synthesis of the Schiffs base is reported to produce low yields of lamotrigine.

As lamotrigine has emerged to be one of the promising antiepileptic and anti-convulsant agents for treating CNS disorders, its commercial production assumes significance. Despite the several routes known for the synthesis of lamotrigine there is still need for a route which is safe, convenient, efficient, economical and less time consuming.

#### Disclosure of the invention

An object of the invention is to provide a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I, commonly known as lamotrigine, which is safe and convenient.

Another object of the invention is to provide a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I, commonly known as lamotrigine, which is less time consuming.

5

10

15

Another object of the invention is to provide a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I commonly known as lamotrigine, which is efficient and economical.

5

Another object of the invention is to provide a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine of the formula I, commonly known as lamotrigine, which is suitable for industrial scale manufacture.

10

According to the invention, there is provided a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I:

15

20

Formula I

commonly known as lamotrigine which comprises:

a) reduction of 2,3-dichloronitrobenzene of the formula IX:

5

### Formula IX

in C<sub>1</sub>-C<sub>6</sub> aliphatic alkanol with hydrogen gas at a pressure of 55-90 psi in the presence of a metal catalyst at 27 - 35°C;

10

b) diazotisation of the resulting 2,3-dichloroaniline of the formula X:

15

### Formula X

with sodium nitrite and a mineral acid at -5° to 5°C followed by cyano-dediazonation with a metal cyanide at 65 - 80°C;

20

c) hydrolysis of the resulting 2,3-dichlorobenzonitrile of the formula XI:

25

### Formula XI

under acidic or alkaline conditions;

10

15

20

d) chlorination of the resulting 2,3-dichlorobenzoic acid of the formula VI:

COOH

Formula VI

with a chlorinating agent at 55 - 130°C;

e) cyano-de-halogenation of the resulting 2,3-dichlorobenzoyl chloride of the formula VII:

Formula VII

with a metal cyanide in the presence of an alkali metal iodide by refluxing in an aprotic solvent under an inert atmosphere;

f) condensation of the resulting 2,3-dichlorobenzoyl cyanide of the formula VIII:

Formula VIII

10

15

20

25

with aminoguanidine bicarbonate in an organic solvent in acidic conditions in the presence of a catalyst at 90° - 125°C followed by insitu cyclisation of the resulting Schiff's base of the formula IV:

$$C = N - N - C$$

$$CN H$$

$$NH_2$$

Formula IV

by refluxing in an aliphatic alkanol in the presence of a base; and

g) purification of the resulting crude lamotrigine of the formula I:

Formula I

by a known method such as recrystallisation from an aliphatic alkanol or chromatographic separation.

The reduction of 2,3-dichloronitrobenzene may be carried out by dissolution of 2,3-dichloronitrobenzene preferably in methanol. The pressure of the hydrogen gas for reduction may be preferably 50-70psi, still preferably 80 psi and the temperature for the reduction may be preferably 30°C. The metal catalysts used in the reduction reaction may be

nickel, Raney nickel, platinum oxide, rhodium-platinum oxide, palladium-carbon, or palladium salts, preferably Raney nickel. An alkali or alkaline earth metal hydroxide such as NaOH, KOH, Ca(OH)<sub>2</sub> or Mg(OH)<sub>2</sub> may be optionally used in the reduction reaction.

5

For the diazotisation of 2,3-dichloroaniline, mineral acids such as HCl or H<sub>2</sub>SO<sub>4</sub>, preferably H<sub>2</sub>SO<sub>4</sub>, may be used. The diazotisation may be carried out preferably at 0°C. The excess sodium nitrite may be optionally decomposed using agents such as urea, sulfamic acid or a small amount of a primary amine dissolved in acid.

10

15

The cyano-de-diazonation reaction may be carried out using metal cyanides such as NaCN, KCN or Cu(one)CN or a mixture thereof. Preferably a mixture of Cu(one)CN and NaCN may be used. The cyano-de-diazonation may be carried out preferably at 65°C. Excess of cyanide may be optionally decomposed using sodium hypochlorite solution. A phase transfer catalyst such as crown ether or a quaternary ammonium salt in the presence of a nickel catalyst may be optionally used during the cyano-de-diazonation reaction.

20

25

The alkaline hydrolysis of 2,3-dichlorobenzonitrile may be carried out using NaOH or KOH in the presence of an aliphatic alkanol such as methanol or ethanol. Preferably methanolic NaOH at reflux temperatures may be used. The unreacted cyano compound may be extracted using toluene, ethyl acetate or a mixture of toluene and ethyl

acetate, preferably toluene. Mineral acids such as H<sub>2</sub>SO<sub>4</sub> or HCl may be used for acidic hydrolysis.

2,3-dichlorobenzoic acid may be chlorinated using SOCl<sub>2</sub> PCl<sub>3</sub> or PCl<sub>5</sub>. Preferably SOCl<sub>2</sub> at 80°C is used.

The cyano-de-halogenation reaction of 2,3-dichlorobenzoyl chloride is carried out under an inert atmosphere such as nitrogen atmosphere. The metal cyanide used may be Cu(one)CN, NaCN, KCN or a mixture of Cu(one)CN and NaCN. The alkali metal iodide may be NaI or KI. Preferably Cu(one)CN in the presence of KI may be used. The aprotic solvent for the reaction may be monochlorobenzene, xylene or any other aprotic solvent, preferably monochlorobenzene.

15

5

10

The condensation of 2,3-dichlorobenzoyl cyanide with aminoguanidine bicarbonate is carried out in the presence of a catalyst such as p-toluenesulfonic acid or a lewis acid catalyst such as AlCl<sub>3</sub>, TiCl<sub>4</sub>, FeCl<sub>3</sub>, ZnCl<sub>2</sub>, ZrCl<sub>4</sub> or any protonated acid such as HCl or H<sub>2</sub>SO<sub>4</sub>, in an organic solvent such as toluene or ethyl benzene, in acidic medium using HCl, HNO<sub>3</sub> or H<sub>2</sub>SO<sub>4</sub>. Preferably toluene and H<sub>2</sub>SO<sub>4</sub> with p-toluenesulfonic acid at 100 - 120°C may be used. Insitu cyclisation of the Schiff's base may be carried out in an aliphatic alkanol such as methanol with a strong base such as NaOH, KOH or NaOMe. Preferably methanol and NaOMe may be used.

25

For the recrystallisation of the crude lamotrigine, an aliphatic alkanol such as isopropanol, ethanol or methanol, preferably methanol may be used.

5

Pharmaceutically acceptable acid addition salts of lamotrigine of the formula I may be prepared by treating lamotrigine of the formula I with acids such as hydrochloric, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, succinic, oxalic, fumaric, maleic, oxaloacetic, methane sulphonic, p-toluene sulphonic or benzene sulphonic acid.

10

15

20

25

According to the invention a new route is employed in the preparation of lamotrigine of the formula I. The substrate for the preparation thereof viz 2,3-dichloronitrobenzene and also the other reagents of the process of the invention are safe, inexpensive and easily available, thus eliminating the use of hazardous and expensive reagents reported in the prior art. The reactions leading to 2,3-dichlorobenzoic acid need not be carried out in a dry environment. Also chlorination of 2,3-dichlorobenzoic acid is conveniently carried out in a non-inert atmosphere without affecting the efficiency of the process. The use of catalyst during reduction of 2,3-dichloronitrobenzene at room temperature proceeds without dehalogenation thereby giving increased yield and purity of 2,3-Also the other intermediates of the process of the dichloroaniline. invention are obtained in good yields and purity. The conversion of 2,3dichlorobenzoyl chloride to 2,3-dichlorobenzoyl cyanide requires about 6 hours, as against 96 hours reported in a process of the prior art. Similarly the preparation of the Schiff's base from 2,3-dichlorobenzoyl chloride and

10

20

further insitu cyclisation of the Schiff's base to lamotrigine also is less time consuming (8 hrs), as against 7.5-10 days reported in the prior art processes to prepare the Schiff's base itself. Therefore, the process of the invention is less time consuming and economical. The process of the invention gives a yield of 23% of lamotrigine (starting from 2,3-dichloronitrobenzene) as against a meagre yield of 10% (from 2,3-dichloroiodobenzene) reported in the prior art. Lamotrigine by our invention is also obtained with an excellent purity of 99.67% (by HPLC) after recrystallisation. The process of the invention is, therefore, efficient and economical and also suitable for industrial scale manufacture.

The following experimental example is illustrative of the invention but not limitative of the scope thereof.

15 Example 1

### Preparation of 2,3-dichloroaniline (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>NH<sub>2</sub>):

2,3-Dichloronitrobenzene (800g, 4.17 moles) was dissolved in methanol (5.6L) and charged into an autoclave. Raney nickel (80g, 10% w/w) was added to the solution. The reaction mixture was hydrogenated at 80 psi for 3.5 hrs at 30°C and filtered through celite. Methanol was distilled off to give 2,3-dichloroaniline (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>NH<sub>2</sub>).

Yield = 656 g

WO 01/49669 PCT/IN00/00001

15

Purity = 98% (when analysed by Gas Chromatography)

### Preparation of 2,3-dichlorobenzonitrile (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>CN):

Conc. H<sub>2</sub>SO<sub>4</sub> (1.365 L) and water (4.5 L) were charged into a suitable round bottom flask and the solution was cooled to 0°C. 2,3-Dichloroaniline (650g, 4.012 moles) was added to the above solution and the reaction mixture was cooled and maintained at 0°C. A saturated solution of sodium nitrite (332.22g, 4.815 moles) was added dropwise to the reaction while maintaining the temperature below 5°C. The reaction mixture was stirred at 0-5°C for 1 hr and neutralised with sodium hydroxide at 0 - 5°C. The neutral solution was added dropwise to the cyanide solution [Cyanide solution obtained by mixing Cu(one)CN (365 g. 4.10 moles), NaCN (340 g, 6.93 moles) and water (1.0 L)] at 65°C, under vigorous stirring for a period of 15 mins. The reaction mixture was warmed to 70°C and stirred for another 15 mins. The 2.3dichlorobenzonitrile so formed was extracted using ethylacetate (2.0 L). The organic layer was dried over sodium sulfate and stripped to give a semi-solid mass of 2,3-dichlorobenzonitrile (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>CN).

Yield = 650g

Purity = 92% (when analysed by Gas

Chromatography).

25

5

10

15

### Preparation of 2,3-dichlorobenzoic acid (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>COOH):

Sodium hydroxide (168.0g, 4.2 moles, 1.2 eq) was dissolved in a mixture containing methanol (1.08 L) and water (600 ml) maintained at 5-10°C. This solution was then added to a flask containing 2,3-dichlorobenzonitrile (602.0g, 3.5 moles). The reaction mixture was heated and refluxed for 10 hrs with slow stream of air bubbles being purged into the reaction mixture. Methanol was distilled off and water (1.0L) was added to the reaction mixture. The reaction mixture was extracted with toluene (2 x 500ml). The toluene fraction containing unreacted cyano compound was concentrated and recycled. The aqueous portion was treated with conc. HCl (32%, 800 ml) to obtain a white solid precipitate of 2,3-dichlorobenzoic acid(C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>COOH) which was filtered and dried.

Yield = 500g

Purity = 97% (when analysed by High Performance Liquid Chromatography)

### Preparation of 2,3-dichlorobenzoyl chloride (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>COCl):

20

25

15

5

10

2,3-Dichlorobenzoic acid (500g, 2.618 moles) was charged into a 2L four necked round bottom flask containing thionyl chloride (623g, 5.235 moles) and heated at 80°C for 1.0 hr to give 2,3-dichlorobenzoyl chloride (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>COCl), after removal of excess of thionyl chloride.

10

15

20

25

17

Yield = 500 g

Purity = 98% (when analysed by Gas

Chromatography)

### Preparation of 2,3-dichlorobenzoyl cyanide (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>COCN):

Copper cyanide (215g, 2.4 moles), potassium iodide (199g, 1.2 moles) and monochlorobenzene (1.0L) were added to a 3L four necked round bottom flask containing 2,3-dichlorobenzoyl chloride (500g, 2.392 moles). The reaction mixture was heated to reflux under nitrogen blanket and maintained at 132-135°C for 6 hrs. The reaction mixture was then filtered and monochlorobenzene distilled off to obtain 2.3-dichlorobenzoyl cyanide(C<sub>6</sub>H<sub>3</sub>Ch<sub>2</sub>COCN).

Yield = 470g

Purity = 97% (when analysed by Gas

Chromatography)

Preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine  $(C_9H_7Cl_2N_5)$ :

Aminoguanidine bicarbonate (136g, 1.0 mole) and toluene (1L) were charged into a 3L four necked round bottom flask. To this slurry was added conc sulfuric acid (98g, 1.0 mole) in a slow stream and p-toluene sulfonic acid (25g). The mixture was stirred for 15 mins and heated to 110°C. Water was azeotroped out from the mixture and the reaction

mixture was cooled to 80°C. To this, 2,3-dichlorobenzoyl cyanide (100g, 0.5 mole) was added and the reaction mixture was refluxed for 3.5 hrs. Toluene was removed completely and the reaction mixture was cooled to 25°C. To it was added sodium methoxide (500 g) (solution in methanol 25% w/w) and refluxed for 3 hrs. Methanol was removed completely and the reaction mixture was cooled to 20°C. Water (400 ml) was added to the reaction mixture and stirred at 20-25°C for 1 hr. The precipitated solid was filtered and washed with water till free of base to give crude 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (C<sub>9</sub>H<sub>7</sub>Cl<sub>2</sub>N<sub>5</sub>).

10

15

20

5

Yield = 72g

Purity = 94% (when analysed by High Performance Liquid Chromatography)

The crude product was recrystallised from methanol to give pure 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine(C<sub>2</sub>H<sub>7</sub>Cl<sub>2</sub>N<sub>5</sub>).

Yield = 64 g

Purity = 99.7% (when analysed by High Performance Liquid Chromatography).

### **CLAIMS**

1) A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I:

10

5

### Formula I

commonly known as lamotrigine which comprises:

a) reduction of 2,3-dichloronitrobenzene of the formula IX:

diazotisation of the resulting 2,3-dichloroaniline of the

15

### Formula IX

20

in C<sub>1</sub>-C<sub>6</sub> aliphatic alkanol with hydrogen gas at a pressure of 55-90 psi in the presence of a metal catalyst at 27 - 35°C;

formula X:

**b**)

Formula X

with sodium nitrite and a mineral acid at -5° to 5°C followed by cyano-dediazonation with a metal cyanide at 65 - 80°C;

c) hydrolysis of the resulting 2,3-dichlorobenzonitrile of

the formula XI:

Formula XI

15

10

5

under acidic or alkaline conditions;

d) chlorination of the resulting 2,3-dichlorobenzoic acid of the formula VI:

20

Formula VI

with a chlorinating agent at 55 - 130°C;

e) cyano-de-halogenation of the resulting 2,3-dichlorobenzoyl chloride of the formula VII:

### Formula VII

with a metal cyanide in the presence of an alkali metal iodide by refluxing in an aprotic solvent under an inert atmosphere;

10

5

f) condensation of the resulting 2,3-dichlorobenzoyl cyanide of the formula VIII:

15

20

25

### Formula VIII

with aminoguanidine bicarbonate in an organic solvent in acidic conditions in the presence of a catalyst at 90° - 125°C followed by insitu cyclisation of the resulting Schiff's base of the formula IV:

$$CI \longrightarrow C = N - N - C \nearrow NH_2$$

Formula IV

by refluxing in an aliphatic alkanol in the presence of a base; and

g) purification of the resulting crude lamotrigine of the formula I:

Formula I

by a known method such as recrystallisation from an aliphatic alkanol or chromatographic separation.

10

15

20

25

- 2) A process as claimed in claim 1 wherein the reduction of 2,3-dichloronitrobenzene is carried out in methanol using hydrogen gas at a pressure of 80 psi in the presence of Raney nickel at 30°C.
- 3) A process as claimed in claims 1 or 2, wherein the diazotisation of 2,3-dichloroaniline is carried out using sodium nitrite and H<sub>2</sub>SO<sub>4</sub> at 0°C.
  - 4) A process as claimed in any one of claims 1 to 3, wherein the cyano-de-diazonation is carried out using a mixture of Cu(one)CN and NaCN at 65°C.
  - 5) A process as claimed in any one of claims 1 to 4, wherein the hydrolysis of 2,3-dichlorobenzonitrile is carried out by refluxing with methanolic NaOH.

- 6) A process as claimed in any one of claims 1 to 5, wherein chlorination of 2,3-dichlorobenzoic acid is carried out vivi SOCl<sub>2</sub> at 80°C.
- 7) A process as claimed in any one of claims 1 to 6, wherein the cyano-de-halogenation of 2,3-dichlorobenzey chloride is carried out with Cu(one)CN and KI in monochlorobenzene under nitrogen atmosphere at 132-135°C.
- 8) A process as claimed in any one of claims 1 to 7, wherein 2,3-dichlorobenzoyl cyanide is condensed with aminoguanidine bicarbonate in toluene in the presence of sulfuric and and p-toluene sulfonic acid at 100 120°C.
- 9) A process as claimed in any one of claims 1 to 8, wherein insitu cyclisation of the schiff's base is carred out in methanol in the presence of NaOMe.
- 10) A process as claimed in any one of claims 1 to 9, wherein crude lamotrigine is purified by recrystal sation from methanol.

International application No. PCT/IN 00/00001

### **CLASSIFICATION OF SUBJECT MATTER**

IPC<sup>7</sup>: C07D 253/07

According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

### REGISTRY, CA, CONSIDERED, EPODOC

#### C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
Α	EP 963980 A2 (The Wellcome Foundation Limited, UK) 15 December 1999 (15.12.99); reaction scheme p.7, steps b,c,d,e; page 8, lines 1-23.		
А	WO 9620934 A1 (Wellcome Foundation Limited, UK) 11 July 1996 (11.07.96); example 6; cited in the application.	1-10	
А	WO 9620935 A1 (Wellcome Foundation Limited, UK) 11 July 1996 (11.07.96); claims 1-6; cited in the application.	1-10	
Α	EP 247892 A1 (Wellcome Foundation Ltd., UK) 2 December 1987 (02.12.87), & US 4847249 A; examples 1,2; cited in the application.	1-10	
А	EP 142306 A2 (Wellcome Foundation Ltd., UK) 22 May 1985 (22.05.85); example 1.	1-10	
Α	US 4486354 A (Wellcome Foundation Ltd., UK) 4 December 1984 (04.12.84), & US 4602017 A; example 1	1-10	
	·		

Further documents are listed in the continuation of Box C.	See patent family annex.					
* Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier application or patent but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed	considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art					
Date of the actual completion of the international search	Date of mailing of the international search report					
13 September 2000 (13.09.2000)	19 December 2000 (19.12.2000)					
Name and mailing adress of the ISA/AT	Authorized officer					
Austrian Patent Office	MÜLLER-HIEL					
Kohlmarkt 8-10; A-1014 Vienna						
Facsimile No. 1/53424/535	Telephone No. 1/53424/434					

Form PCT/ISA/210 (second sheet) (July 1998)

International application No.

PCT/IN 00/00001

Γ	C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT							
	Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.					
	Α	CA 1119592 A1 (Lilly, Eli, and Co., USA) 9 March 1982 (09.03.82); Compound RN 608-27-5 (diazotization and reaction of, with cyanide).	1-10					
.	Α	EP 325892 A2 (Ciba-Geigy AG., Switz.) 2 Augsut 1989 (02.08.89); Compound RN 608-27-5, 3-Amino-1,2-dichlorobenzene(manuf. of, by hydrogenation of dichloronitrobenzene).	1-10					
		,						
		·						
		·						
		·						
		, 						
Fo	orm PCT/IS	A/210 (continuation of second sheet) (July 1998)						

Information on patent family members

International application No.
PCTIN 00/00001

		t document cited search report	Publication date		Patent memb		Publication date	
EP	A2	963980	15-12-1999	AP	A0	9901481	31-03-1999	
EP	A3	963980	31-05-2000	AU	Al	20319/99	06-01-2000	
				BR	A	9900984	02-05-2000	
				CN	Α	1238454	15-12-1999	
				GB	A0	9812413	05-08-1998	
				HU HU	A0	9900592	28-04-1999	
				JP	AB B2	9900592 2989189	28-04-2000	
				JP	A2	00009714	13-12-1999 14-01-2000	
				NO	A0	991151	10-03-1999	
				МО	Α	991151	13-12-1999	
				PL	Al	331870	20-12-1999	
WO	Al	9620934	11-07-1996	AU	Al	43115/96	24-07-1996	
		•		EP FI	A1 A0	800520	15-10-1997	
				FI	A	9 <b>72</b> 719 9 <b>7</b> 2719	24-06-1997	
				GB	0A	9426447	27-08-1997 01-03-1995	
				иu	A2	77346	30-03-1998	
				JР	т2	11501007	26-01-1999	
				บร	Α	5912345	15-06-1999	
	<del></del>	0620025	11 00	GB	A0	9426439	01-03-1995	
MO:	A1	9620935	11-07-1996	AU	A1	43116/96	24-07-1996	
				EP FI	A1 A0	800521	15-10-1997	
				FI	AU A	972720 972720	24-06-1997	
				GB	Ã0	9426448	27-08-1997 01-03-1995	
				HU	A2	77347	30-03-1998	
				JР	T2	11507011	22-06-1999	
		0.470.00		US	<u> </u>	5925755	20-07-1999	
EP EF	Al Bl	247892 247892	02-12-1987	AT	E	62902	15-05-1991	
C.P	D1	247092	24-04-1991	AU AU	Al B2	73684/87 597982	03-12-1987	
				CA	A1	1286670	14-06-1990 23-07-1991	
				DE	C0	3769516	29-05-1991	
				DK	AO	2759/87	29-05-1987	
				DK	Α	2759/87	01-12-1987	
				DK	В	166278	29-03-1993	
		٠,		DK	C	166278	23-08-1993	
				FI FI	AO A	872406 872406	29-05-1987 01-12-1987	
				FI	В	90770	15-12-1993	
				FI	c	90770	25-03-1994	
				GB	A0	8613183	02-07-1986	
				GR	Т3	3001942	23-11-1992	
				HU	A2	45978	28-09-1988	
				HU IE	B B	196769 60626	30-01-1989	
				IL	AO	82710	27-07-1994 30-11-1987	
				IL	Al	82710	15-01-1992	
				JР	A2	62289570	16-12-1987	
				JP	B4	7051571	05-06-1995	
				KR	B1	9102254	08-04-1991	
				NZ US	A	220497	28-05-1990	
				ZA	A A	4847249 8703896	11-07-1989 25-01-1989	
EP	A2	142306	22-05-1985	AU	A1	34758/84	09-05-1985	
EP	A3	142306	20-11-1986	AU	B2	564667	20-08-1987	
				CA	A1	1261328	26-09-1989	
				DD	A5	224033	26-06-1985	
				DK	AO	5121/84	26-10-1984	
				DK	A	5121/84	28-04-1985	
				ES ES	A1 A5	537104 537104	16-04-1986	
				ES	A1	8606304	16-05-1986 01-10-1986	
				FI	AO	844212	26-10-1984	
				FI	A	844212	28-04-1985	
				GB	AO	8328757	30-11-1983	
				GR	Α	80723	07-02-1985	
				HU	A2	36102	28-08-1985	
				HU	В	191566	30-03-1987	
				IL IL	AO Al	73332 73332	31-01-1985	
				JP	A1 A2	73332 60109577	30-06-1988 15-06-1985	
				KR	B1	8900991	15-04-1989	

PCT/ISA/210 (patent family annex) (July 1998)

Information on patent family members

International application No. PCTIN 00/00001

Patent document cited in search report	Publication date		Patent f		Publication date	
		NZ PH	A A	210000 21926	31-08-1987	
		PL	Al	250213	08-04-1988 03-12-1985	
		PL	81	144899	30-07-1988	
		PT	A	79416	01-11-1984	
		РT	В	79416	13-11-1986	
		SU	<b>A3</b>	1371500	30-01-1988	
		US	Α	4649139	10-03-1987	
		ZA	<u>A</u>	8408388	25-06-1986	
US A 4486354	04-12-1984	AR	A1	227521	15-11-1982	
		AT AT	A	2896/80	15-07-1982	
		AU	B Al	370097 58906/80	25-02-1983 04-12-1980	
		UA	B2	530999	04-12-1980	
		BG	B2	60427	31-03-1995	
•		CA	A1	1112643	17-11-1981	
		CA	A2	1133938	19-10-1982	
		CS	В2	234018	14-03-1985	
		CZ	A3	9103848	13-10-1993	
		DD DE	C	151309	14-10-1981	
		DE	C0	3063084 3071000	16-06-1983	
·		DK	A	2338/80	19-09-1985 02-12-1980	
		DK	в	153787	05-09-1988	
		ÐK	c	153787	16-01-1989	
•		EP	Al	21121	07-01-1981	
		EP	Al	59987	15-09-1982	
		EP	Bl	21121	11-05-1983	
		EP	B1	59987	14-08-1985	
	•	ES ES	A1	491998	16-05-1981	
		ES	A5 A1	491998 8104993	15-06-1981 01-08-1981	
		FI	A	801758	02-12-1980	
		FI	A	840888	06-03-1984	
		FI	AO	840888	06-03-1984	
		FI	В	67844	28-02-1985	
		FI	С	67844	10-06-1985	
		FI	В	73203	29-05-1987	
		FI	C	73203	10-09-1987	
		GR HU	A B	68380 182086	28-12-1981	
:		IE	В	49823	28-12-1983 25-12-1985	
		IL	Ã0	60201	31-07-1980	
		IL	Al	€0201	31-05-1984	
		ΙT	A0	8048848	30-05-1980	
		ΙT	A	1147087	19-11-1986	
		JP	A2	56025169	10-03-1981	
		JP	A2	61033163	17-02-1986	
•		JP TD	B4	1044179	26-09-1989	
		JP LT	B4 A3	1044706 2066	29-09-1989 15-06-1993	
		MY	A	62/85	31-12-1985	
		NZ	A	193890	06-07-1984	
		N2	Α	198159	09-11-1984	
		PL	Al	224633	13-02-1981	
		PL	В1	124029	31-12-1982	
		SU	EA	1055331	15-11-1983	
		US	A	4602017	22-07-1986	
		YU	A	1456/80	28-02-1983	
·		ZA ZW	A A	8003250 129/80	27-01-1982 06-01-1982	
CA A1 1119592	09-03-1982	AR	Al	218496	13-06-1980	
CA 31 1113332	03 03 2302	AR	Al	222829	30-06-1981	
		BE	Al	868471	27-12-1978	
•		CA	A2	1122528	27-04-1982	
		СН	Α	641165	15-02-1984	
		CH	A	641677	15-03-1984	
		DE	. A1	2827931	18-01-1979	
	•	DE	C2	2827931	11-11-1982	
		FR FR	A1 B1	2395997 2395997	26-01-1979 26-06-1981	
		GB	B1 A	1603947	02-12-1981	
		ни	P	177824	28-12-1981	
		IE	В	47057	14-12-1983	

PCT/ISA/210 (patent family annex) (July 1998)

Information on patent family members

International application No.
PCTIN 00/00001

	Patent document cited in search report		Publication date	Patent family member(s)			Publication date
				IL	Al	55002	30-11-1981
				IT	ΑO	7825254	30-06-1978
				IT	Α	1098353	07-09-1985
				JP	A2	54014993	03-02-1979
				JP	В4	59053911	27-12-1984
				NL	A	7807002	03-01-1979
EP	A2	325892	02-08-1989	CA	A1	1304412	30-06-1992
E.P	A3	325892	05-09-1990	DE	C0	3878218	18-03-1993
ĘΡ	В1	325892	03-02-1993	JP	A2	2000740	05-01-1990
				JP	B2	2694154	24-12-1997
				US	Α	4960936	02-10-1990

PCT/ISA/210 (patent family annex) (July 1998)